世界の代謝障害治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Metabolic Disorders Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12466 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、代謝障害治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。代謝障害治療の種類別市場規模（異染性白質ジストロフィー、グロボイド白質ジストロフィー、肝性脳症、その他）、用途別市場規模（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・代謝障害治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie、Novo Nordisk、Actelion Pharmaceuticals、Sanofi、Biocon、Merck、Boehringer Ingelheim、AstraZeneca、CymaBay Therapeutics、Eli Lilly and Company ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：異染性白質ジストロフィー、グロボイド白質ジストロフィー、肝性脳症、その他 ・用途別分析2016年-2026年：糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他 ・代謝障害治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・代謝障害治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・代謝障害治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・代謝障害治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・代謝障害治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Metabolic Disorders Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Metabolic Disorders Therapeutics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Metabolic Disorders Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Metabolic Disorders Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others

Market segment by Application, can be divided into
Diabetes
Obesity
Hypercholesterolemia
Lysosomal Storage Diseases
Others

Market segment by players, this report covers
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics
Eli Lilly and Company

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Metabolic Disorders Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Metabolic Disorders Therapeutics, with revenue, gross margin and global market share of Metabolic Disorders Therapeutics from 2019 to 2021.
Chapter 3, the Metabolic Disorders Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Metabolic Disorders Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Metabolic Disorders Therapeutics research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Metabolic Disorders Therapeutics
1.2 Classification of Metabolic Disorders Therapeutics by Type
1.2.1 Overview: Global Metabolic Disorders Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Type in 2020
1.2.3 Metachromatic Leukodystrophy
1.2.4 Globoid Leukodystrophy
1.2.5 Hepatic Encephalopathy
1.2.6 Others
1.3 Global Metabolic Disorders Therapeutics Market by Application
1.3.1 Overview: Global Metabolic Disorders Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Diabetes
1.3.3 Obesity
1.3.4 Hypercholesterolemia
1.3.5 Lysosomal Storage Diseases
1.3.6 Others
1.4 Global Metabolic Disorders Therapeutics Market Size & Forecast
1.5 Global Metabolic Disorders Therapeutics Market Size and Forecast by Region
1.5.1 Global Metabolic Disorders Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Metabolic Disorders Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Metabolic Disorders Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Metabolic Disorders Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Metabolic Disorders Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Metabolic Disorders Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Metabolic Disorders Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Metabolic Disorders Therapeutics Market Drivers
1.6.2 Metabolic Disorders Therapeutics Market Restraints
1.6.3 Metabolic Disorders Therapeutics Trends Analysis
2 Company Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Metabolic Disorders Therapeutics Product and Solutions
2.1.4 AbbVie Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AbbVie Recent Developments and Future Plans
2.2 Novo Nordisk
2.2.1 Novo Nordisk Details
2.2.2 Novo Nordisk Major Business
2.2.3 Novo Nordisk Metabolic Disorders Therapeutics Product and Solutions
2.2.4 Novo Nordisk Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novo Nordisk Recent Developments and Future Plans
2.3 Actelion Pharmaceuticals
2.3.1 Actelion Pharmaceuticals Details
2.3.2 Actelion Pharmaceuticals Major Business
2.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product and Solutions
2.3.4 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Actelion Pharmaceuticals Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Metabolic Disorders Therapeutics Product and Solutions
2.4.4 Sanofi Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Biocon
2.5.1 Biocon Details
2.5.2 Biocon Major Business
2.5.3 Biocon Metabolic Disorders Therapeutics Product and Solutions
2.5.4 Biocon Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Biocon Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Metabolic Disorders Therapeutics Product and Solutions
2.6.4 Merck Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Merck Recent Developments and Future Plans
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Product and Solutions
2.7.4 Boehringer Ingelheim Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Boehringer Ingelheim Recent Developments and Future Plans
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Metabolic Disorders Therapeutics Product and Solutions
2.8.4 AstraZeneca Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 AstraZeneca Recent Developments and Future Plans
2.9 CymaBay Therapeutics
2.9.1 CymaBay Therapeutics Details
2.9.2 CymaBay Therapeutics Major Business
2.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Product and Solutions
2.9.4 CymaBay Therapeutics Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 CymaBay Therapeutics Recent Developments and Future Plans
2.10 Eli Lilly and Company
2.10.1 Eli Lilly and Company Details
2.10.2 Eli Lilly and Company Major Business
2.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Product and Solutions
2.10.4 Eli Lilly and Company Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Eli Lilly and Company Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Metabolic Disorders Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Metabolic Disorders Therapeutics Players Market Share
3.2.2 Top 10 Metabolic Disorders Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Metabolic Disorders Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Metabolic Disorders Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Metabolic Disorders Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Metabolic Disorders Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Metabolic Disorders Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Metabolic Disorders Therapeutics Revenue by Type (2016-2026)
6.2 North America Metabolic Disorders Therapeutics Revenue by Application (2016-2026)
6.3 North America Metabolic Disorders Therapeutics Market Size by Country
6.3.1 North America Metabolic Disorders Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Metabolic Disorders Therapeutics Revenue by Type (2016-2026)
7.2 Europe Metabolic Disorders Therapeutics Revenue by Application (2016-2026)
7.3 Europe Metabolic Disorders Therapeutics Market Size by Country
7.3.1 Europe Metabolic Disorders Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Metabolic Disorders Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Metabolic Disorders Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region
8.3.1 Asia-Pacific Metabolic Disorders Therapeutics Revenue by Region (2016-2026)
8.3.2 China Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Metabolic Disorders Therapeutics Revenue by Type (2016-2026)
9.2 South America Metabolic Disorders Therapeutics Revenue by Application (2016-2026)
9.3 South America Metabolic Disorders Therapeutics Market Size by Country
9.3.1 South America Metabolic Disorders Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Metabolic Disorders Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Metabolic Disorders Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country
10.3.1 Middle East & Africa Metabolic Disorders Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Metabolic Disorders Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Metabolic Disorders Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Metabolic Disorders Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Metabolic Disorders Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Metabolic Disorders Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Metabolic Disorders Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. AbbVie Corporate Information, Head Office, and Major Competitors
Table 7. AbbVie Major Business
Table 8. AbbVie Metabolic Disorders Therapeutics Product and Solutions
Table 9. AbbVie Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 11. Novo Nordisk Major Business
Table 12. Novo Nordisk Metabolic Disorders Therapeutics Product and Solutions
Table 13. Novo Nordisk Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Actelion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Actelion Pharmaceuticals Major Business
Table 16. Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product and Solutions
Table 17. Actelion Pharmaceuticals Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Sanofi Corporate Information, Head Office, and Major Competitors
Table 19. Sanofi Major Business
Table 20. Sanofi Metabolic Disorders Therapeutics Product and Solutions
Table 21. Sanofi Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Biocon Corporate Information, Head Office, and Major Competitors
Table 23. Biocon Major Business
Table 24. Biocon Metabolic Disorders Therapeutics Product and Solutions
Table 25. Biocon Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Merck Corporate Information, Head Office, and Major Competitors
Table 27. Merck Major Business
Table 28. Merck Metabolic Disorders Therapeutics Product and Solutions
Table 29. Merck Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 31. Boehringer Ingelheim Major Business
Table 32. Boehringer Ingelheim Metabolic Disorders Therapeutics Product and Solutions
Table 33. Boehringer Ingelheim Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 35. AstraZeneca Major Business
Table 36. AstraZeneca Metabolic Disorders Therapeutics Product and Solutions
Table 37. AstraZeneca Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. CymaBay Therapeutics Corporate Information, Head Office, and Major Competitors
Table 39. CymaBay Therapeutics Major Business
Table 40. CymaBay Therapeutics Metabolic Disorders Therapeutics Product and Solutions
Table 41. CymaBay Therapeutics Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 43. Eli Lilly and Company Major Business
Table 44. Eli Lilly and Company Metabolic Disorders Therapeutics Product and Solutions
Table 45. Eli Lilly and Company Metabolic Disorders Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Metabolic Disorders Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Metabolic Disorders Therapeutics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Metabolic Disorders Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Metabolic Disorders Therapeutics Players Head Office, Products and Services Provided
Table 50. Metabolic Disorders Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Metabolic Disorders Therapeutics New Entrants and Expansion Plans
Table 52. Global Metabolic Disorders Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Metabolic Disorders Therapeutics Revenue Share by Type (2016-2021)
Table 54. Global Metabolic Disorders Therapeutics Revenue Forecast by Type (2021-2026)
Table 55. Global Metabolic Disorders Therapeutics Revenue by Application (2016-2021)
Table 56. Global Metabolic Disorders Therapeutics Revenue Forecast by Application (2021-2026)
Table 57. North America Metabolic Disorders Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Metabolic Disorders Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Metabolic Disorders Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Metabolic Disorders Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Metabolic Disorders Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Metabolic Disorders Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Metabolic Disorders Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Metabolic Disorders Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Metabolic Disorders Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Metabolic Disorders Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Metabolic Disorders Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Metabolic Disorders Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Metabolic Disorders Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Metabolic Disorders Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Metabolic Disorders Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Metabolic Disorders Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Metabolic Disorders Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Metabolic Disorders Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Metabolic Disorders Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Metabolic Disorders Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Metabolic Disorders Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Metabolic Disorders Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Metabolic Disorders Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Metabolic Disorders Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Metabolic Disorders Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Metabolic Disorders Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Metabolic Disorders Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Metabolic Disorders Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Metabolic Disorders Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Metabolic Disorders Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Metabolic Disorders Therapeutics Picture
Figure 2. Global Metabolic Disorders Therapeutics Revenue Market Share by Type in 2020
Figure 3. Metachromatic Leukodystrophy
Figure 4. Globoid Leukodystrophy
Figure 5. Hepatic Encephalopathy
Figure 6. Others
Figure 7. Metabolic Disorders Therapeutics Revenue Market Share by Application in 2020
Figure 8. Diabetes Picture
Figure 9. Obesity Picture
Figure 10. Hypercholesterolemia Picture
Figure 11. Lysosomal Storage Diseases Picture
Figure 12. Others Picture
Figure 13. Global Metabolic Disorders Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Metabolic Disorders Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Metabolic Disorders Therapeutics Revenue Market Share by Region (2016-2026)
Figure 16. Global Metabolic Disorders Therapeutics Revenue Market Share by Region in 2020
Figure 17. North America Metabolic Disorders Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Metabolic Disorders Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Metabolic Disorders Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Metabolic Disorders Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Metabolic Disorders Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Metabolic Disorders Therapeutics Market Drivers
Figure 23. Metabolic Disorders Therapeutics Market Restraints
Figure 24. Metabolic Disorders Therapeutics Market Trends
Figure 25. AbbVie Recent Developments and Future Plans
Figure 26. Novo Nordisk Recent Developments and Future Plans
Figure 27. Actelion Pharmaceuticals Recent Developments and Future Plans
Figure 28. Sanofi Recent Developments and Future Plans
Figure 29. Biocon Recent Developments and Future Plans
Figure 30. Merck Recent Developments and Future Plans
Figure 31. Boehringer Ingelheim Recent Developments and Future Plans
Figure 32. AstraZeneca Recent Developments and Future Plans
Figure 33. CymaBay Therapeutics Recent Developments and Future Plans
Figure 34. Eli Lilly and Company Recent Developments and Future Plans
Figure 35. Global Metabolic Disorders Therapeutics Revenue Share by Players in 2020
Figure 36. Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players Metabolic Disorders Therapeutics Revenue Market Share in 2020
Figure 38. Global Top 10 Players Metabolic Disorders Therapeutics Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global Metabolic Disorders Therapeutics Revenue Share by Type in 2020
Figure 41. Global Metabolic Disorders Therapeutics Market Share Forecast by Type (2021-2026)
Figure 42. Global Metabolic Disorders Therapeutics Revenue Share by Application in 2020
Figure 43. Global Metabolic Disorders Therapeutics Market Share Forecast by Application (2021-2026)
Figure 44. North America Metabolic Disorders Therapeutics Sales Market Share by Type (2016-2026)
Figure 45. North America Metabolic Disorders Therapeutics Sales Market Share by Application (2016-2026)
Figure 46. North America Metabolic Disorders Therapeutics Revenue Market Share by Country (2016-2026)
Figure 47. United States Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe Metabolic Disorders Therapeutics Sales Market Share by Type (2016-2026)
Figure 51. Europe Metabolic Disorders Therapeutics Sales Market Share by Application (2016-2026)
Figure 52. Europe Metabolic Disorders Therapeutics Revenue Market Share by Country (2016-2026)
Figure 53. Germany Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Metabolic Disorders Therapeutics Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific Metabolic Disorders Therapeutics Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Metabolic Disorders Therapeutics Revenue Market Share by Region (2016-2026)
Figure 61. China Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Metabolic Disorders Therapeutics Sales Market Share by Type (2016-2026)
Figure 68. South America Metabolic Disorders Therapeutics Sales Market Share by Application (2016-2026)
Figure 69. South America Metabolic Disorders Therapeutics Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa Metabolic Disorders Therapeutics Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa Metabolic Disorders Therapeutics Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa Metabolic Disorders Therapeutics Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE Metabolic Disorders Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source

---